Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Gyros Completes Next Stage of Development Program with Expansion of Product Portfolio

Published: Friday, August 05, 2011
Last Updated: Thursday, August 04, 2011
Bookmark and Share
Company announces availability of software modules and services to strengthen support for scientists using the Gyros immunoassay platform in regulated environments.

Gyros AB, has announced the completion of a development program initiated to fulfill the requirements of scientists using the Company’s immunoassay platform in the biopharmaceutical industry.

The development program has seen the release of a number of software modules and services to augment the company’s product portfolio, to provide enhanced functionality for users of Gyrolab™ xP workstations, and to further facilitate the use of the platform in regulated environments.

Software modules, such as the Gyrolab LIMS Interface to enable networking and Gyrolab Control Report to generate non-editable result files of raw data, as demanded by regulatory authorities, enable users to upgrade their workstations and retain 21 CFR Part 11 compliance.

Also available is a Gyrolab Functionality Check Kit to check instrument performance within minutes - again in compliance with regulatory demands. To save more time, the Company also offers support for Installation Qualification/Operational Qualification (IQ/OQ) and Performance Qualification (PQ) guidance.

Attendees at the recent European Gyrolab Seminar were able to preview the latest release: the Gyrolab Viewer module that enables the binding profile of each data point to be displayed together with sample and run information.

The ability to see and compare individual binding profiles, a unique feature of the Gyros immunoassay platform, enables users to easily and quickly select optimal reagents during assay development as well as providing a troubleshooting tool for quality control.

Commenting on the announcement, Erik Walldén, President and Chief Executive Officer of Gyros AB, said: “An international installed base confirms that our immunoassay platform is becoming an established technology for bioanalysis throughout the biotherapeutic workflow. It is therefore critical to ensure that our clients have all the support they need to transfer immunoassays downstream from research and development through to regulated GxP environments or between sites. As well as broadening our product offering, this program supports our long term objective of setting the industry standard for transforming the performance of immunoassays within the biopharmaceutical industry.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros Announces Changes to its Management Team
Dr. Jon-Sverre Schanche becomes Chief Technology Officer and Vice President Technical Affairs.
Monday, October 24, 2011
Gyros Wins SwedenBIO Award 2011
Company selected to receive the award based on the international success of the Gyros immunoassay platform.
Friday, May 27, 2011
Gyros platform enters leading US Clinical Research Organization
CEDRA Corporation, a division of Worldwide Clinical Trials, invests in Gyrolab workstation
Tuesday, March 16, 2010
Gyros Platform Ramps Up Immunoassay Capacity at ICON Development Solutions
CRO purchases third Gyrolab workstation to develop and run immunoassays.
Friday, March 12, 2010
Gyros and SCRUM Sign Distribution Agreement for the Japanese Market
SCRUM will market, sell and fully support the Gyros product range, within the Japanese life-science market industries.
Wednesday, February 17, 2010
Gyros has Completed the Separate Sales of two Microfluidic System Platforms
Gyros platform for protein quantification is purchased by AstraZeneca and Cambridge Antibody Technology.
Wednesday, August 09, 2006
Gyros Awarded Frost & Sullivan Technology of the Year Award
The award recognizes the company’s technology development and overall technical excellence.
Wednesday, November 16, 2005
Gyros AB licenses technology to Cellectricon AB

Tuesday, April 15, 2003
Gyros expands with German office

Monday, December 02, 2002
Scientific News
Chip-Based Technology Enables Reliable Direct Detection of Ebola Virus
Hybrid device integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral RNA.
Stem Cell Research Hints at Evolution of Human Brain
Researchers at UC San Francisco have succeeded in mapping the genetic signature of a unique group of stem cells in the human brain that seem to generate most of the neurons in our massive cerebral cortex.
Developing a Breathalyzer-Type Low Blood Sugar Warning Device For Diabetes
A multidisciplinary team of researchers at Indiana University-Purdue University Indianapolis has been awarded a $738,000 National Science Foundation grant to develop a breathalyzer-type device to detect the onset of hypoglycemia, or low blood sugar episodes, in people with diabetes.
Smartphone App to Monitor Serious Blood Disorder
A researcher from Florida Atlantic University has come up with a unique way to monitor sickle cell disease -- a serious blood disorder -- using a smart phone.
Preventing Crystallization to Improve Drug Efficiency
Esther Amstad and an international team of researchers have developed a method to increase the solubility of poorly soluble substances, such as many of the newly developed drugs.
‘Lab-on-a-Chip’ Technology Cuts Costs of Lab Tests
With ability to analyze minuscule amounts of fluid, Rutgers breakthrough could also promote central nervous system and joint research.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Device May Detect Urinary Tract Infections Faster
A Lab-on-a-Disc platform developed by a German and Irish team of researchers dramatically cut the time to detect bacterial species that cause urinary tract infections -- a major cause of sepsis.
Automation Abound at AACC in Atlanta
Discover the latest breakthroughs, trends and products from the AACC Annual Meeting & Clinical Lab Expo.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos